These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8227490)

  • 61. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial.
    Pollack MH; Otto MW; Worthington JJ; Manfro GG; Wolkow R
    Arch Gen Psychiatry; 1998 Nov; 55(11):1010-6. PubMed ID: 9819070
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).
    Slaap BR; van Vliet IM; Westenberg HG; den Boer JA
    J Affect Disord; 1995 Jan; 33(1):31-8. PubMed ID: 7714306
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder.
    Greenblatt DJ; Harmatz JS; Shader RI
    Arch Gen Psychiatry; 1993 Sep; 50(9):715-22. PubMed ID: 8357297
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks.
    van Megen HJ; Westenberg HG; den Boer JA; Slaap B; Scheepmakers A
    Psychopharmacology (Berl); 1997 Feb; 129(4):357-64. PubMed ID: 9085405
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Suitable dose and duration of fluvoxamine administration to treat depression.
    Morishita S; Arita S
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Panic disorder in general medicine. Epidemiological data and treatment with clomipramine].
    Rouillon F
    Encephale; 1988; 14(5):371-8. PubMed ID: 3215139
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
    Fux M; Taub M; Zohar J
    Acta Psychiatr Scand; 1993 Oct; 88(4):235-7. PubMed ID: 8256637
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group.
    Rosenbaum JF; Moroz G; Bowden CL
    J Clin Psychopharmacol; 1997 Oct; 17(5):390-400. PubMed ID: 9315990
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sertraline in the treatment of panic disorder: a double-blind multicenter trial.
    Pohl RB; Wolkow RM; Clary CM
    Am J Psychiatry; 1998 Sep; 155(9):1189-95. PubMed ID: 9734541
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Acute treatment response in outpatients with panic disorder: high versus low depressive symptoms.
    Black DW; Wesner R; Bowers W; Monahan P; Gabel J
    Ann Clin Psychiatry; 1995 Dec; 7(4):181-8. PubMed ID: 8721892
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia.
    Bakker A; van Balkom AJ; van Dyck R
    Int Clin Psychopharmacol; 2000 Aug; 15 Suppl 2():S25-30. PubMed ID: 11110016
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Double-blind clonazepam vs placebo in panic disorder treatment.
    Valença AM; Nardi AE; Nascimento I; Mezzasalma MA; Lopes FL; Zin W
    Arq Neuropsiquiatr; 2000 Dec; 58(4):1025-9. PubMed ID: 11105068
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.
    Prosser JM; Yard S; Steele A; Cohen LJ; Galynker II
    BMC Psychiatry; 2009 May; 9():25. PubMed ID: 19470174
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder.
    Sandford JJ; Forshall S; Bell C; Argyropoulos S; Rich A; D'Orlando KJ; Gammans RE; Nutt DJ
    J Psychopharmacol; 2001 Sep; 15(3):205-8. PubMed ID: 11565630
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study.
    van Vliet IM; Westenberg HG; Den Boer JA
    Psychopharmacology (Berl); 1993; 112(4):483-9. PubMed ID: 7871061
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder.
    Fleishaker JC; Greist JH; Jefferson JW; Sheridan AQ
    J Clin Psychopharmacol; 1994 Feb; 14(1):28-35. PubMed ID: 8151001
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia.
    Cottraux J; Note ID; Cungi C; Légeron P; Heim F; Chneiweiss L; Bernard G; Bouvard M
    Br J Psychiatry; 1995 Nov; 167(5):635-41. PubMed ID: 8564320
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
    Davidson J; Yaryura-Tobias J; DuPont R; Stallings L; Barbato LM; van der Hoop RG; Li D
    J Clin Psychopharmacol; 2004 Apr; 24(2):118-25. PubMed ID: 15206657
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictors of short-term treatment response in 66 patients with panic disorder.
    Black DW; Wesner RB; Gabel J; Bowers W; Monahan P
    J Affect Disord; 1994 Apr; 30(4):233-41. PubMed ID: 8014323
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia.
    van Balkom AJ; de Beurs E; Koele P; Lange A; van Dyck R
    J Nerv Ment Dis; 1996 Feb; 184(2):133-5. PubMed ID: 8596113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.